Abrahim Al-Mamgani1, Stefan L S Kwa2, Lisa Tans2, Michael Moring2, Dennie Fransen2, Robert Mehilal2, Gerda M Verduijn2, Rob J Baatenburg de Jong3, Ben J M Heijmen2, Peter C Levendag2. 1. Department of Radiation Oncology - Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands. Electronic address: a.almamgani@nki.nl. 2. Department of Radiation Oncology - Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands. 3. Department of Otolaryngology and Head and Neck Surgery - Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Abstract
PURPOSE: To report, from a retrospective analysis of prospectively collected data, on the feasibility, outcome, toxicity, and voice-handicap index (VHI) of patients with T1a glottic cancer treated by a novel intensity modulated radiation therapy technique developed at our institution to treat only the involved vocal cord: single vocal cord irradiation (SVCI). METHODS AND MATERIALS: Thirty patients with T1a glottic cancer were treated by means of SVCI. Dose prescription was set to 16 × 3.63 Gy (total dose 58.08 Gy). The clinical target volume was the entire vocal cord. Setup verification was done by means of an online correction protocol using cone beam computed tomography. Data for voice quality assessment were collected prospectively at baseline, end of treatment, and 4, 6, and 12 weeks and 6, 12, and 18 months after treatment using VHI questionnaires. RESULTS: After a median follow-up of 30 months (range, 7-50 months), the 2-year local control and overall survival rates were 100% and 90% because no single local recurrence was reported and 3 patients died because of comorbidity. All patients have completed the intended treatment schedule; no treatment interruptions and no grade 3 acute toxicity were reported. Grade 2 acute dermatitis or dysphagia was reported in only 5 patients (17%). No serious late toxicity was reported; only 1 patient developed temporary grade 2 laryngeal edema, and responded to a short-course of corticosteroid. The VHI improved significantly, from 33.5 at baseline to 9.5 and 10 at 6 weeks and 18 months, respectively (P<.001). The control group, treated to the whole larynx, had comparable local control rates (92.2% vs 100%, P=.24) but more acute toxicity (66% vs 17%, P<.0001) and higher VHI scores (23.8 and 16.7 at 6 weeks and 18 months, respectively, P<.0001). CONCLUSION: Single vocal cord irradiation is feasible and resulted in maximal local control rate at 2 years. The deterioration in VHI scores was slight and temporary and subsequently improved to normal levels. Long-term follow-up is needed to consolidate these promising results.
PURPOSE: To report, from a retrospective analysis of prospectively collected data, on the feasibility, outcome, toxicity, and voice-handicap index (VHI) of patients with T1a glottic cancer treated by a novel intensity modulated radiation therapy technique developed at our institution to treat only the involved vocal cord: single vocal cord irradiation (SVCI). METHODS AND MATERIALS: Thirty patients with T1a glottic cancer were treated by means of SVCI. Dose prescription was set to 16 × 3.63 Gy (total dose 58.08 Gy). The clinical target volume was the entire vocal cord. Setup verification was done by means of an online correction protocol using cone beam computed tomography. Data for voice quality assessment were collected prospectively at baseline, end of treatment, and 4, 6, and 12 weeks and 6, 12, and 18 months after treatment using VHI questionnaires. RESULTS: After a median follow-up of 30 months (range, 7-50 months), the 2-year local control and overall survival rates were 100% and 90% because no single local recurrence was reported and 3 patients died because of comorbidity. All patients have completed the intended treatment schedule; no treatment interruptions and no grade 3 acute toxicity were reported. Grade 2 acute dermatitis or dysphagia was reported in only 5 patients (17%). No serious late toxicity was reported; only 1 patient developed temporary grade 2 laryngeal edema, and responded to a short-course of corticosteroid. The VHI improved significantly, from 33.5 at baseline to 9.5 and 10 at 6 weeks and 18 months, respectively (P<.001). The control group, treated to the whole larynx, had comparable local control rates (92.2% vs 100%, P=.24) but more acute toxicity (66% vs 17%, P<.0001) and higher VHI scores (23.8 and 16.7 at 6 weeks and 18 months, respectively, P<.0001). CONCLUSION: Single vocal cord irradiation is feasible and resulted in maximal local control rate at 2 years. The deterioration in VHI scores was slight and temporary and subsequently improved to normal levels. Long-term follow-up is needed to consolidate these promising results.
Authors: Mohamed Shelan; Lukas Anschuetz; Adrian D Schubert; Beat Bojaxhiu; Alan Dal Pra; Frank Behrensmeier; Daniel M Aebersold; Roland Giger; Olgun Elicin Journal: Strahlenther Onkol Date: 2017-05-04 Impact factor: 3.621
Authors: Jenny Bertholet; Paul-Henry Mackeprang; Silvan Mueller; Gian Guyer; Hannes A Loebner; Yanick Wyss; Daniel Frei; Werner Volken; Olgun Elicin; Daniel M Aebersold; Michael K Fix; Peter Manser Journal: Radiat Oncol Date: 2022-07-15 Impact factor: 4.309
Authors: Mischa de Ridder; Cornelis P J Raaijmakers; Frank A Pameijer; Remco de Bree; Floris C J Reinders; Patricia A H Doornaert; Chris H J Terhaard; Marielle E P Philippens Journal: Cancers (Basel) Date: 2022-06-20 Impact factor: 6.575
Authors: B J Heijnen; R Speyer; B Kertscher; R Cordier; K W J Koetsenruijter; K Swan; H Bogaardt Journal: Biomed Res Int Date: 2016-09-19 Impact factor: 3.411
Authors: Ariel E Marciscano; Vivek Charu; Heather M Starmer; Simon R Best; Harry Quon; Alexander T Hillel; Lee M Akst; Ana P Kiess Journal: Front Oncol Date: 2017-06-12 Impact factor: 6.244
Authors: Olgun Elicin; Ekin Ermiş; Christoph Oehler; Daniel M Aebersold; Francesca Caparrotti; Frank Zimmermann; Gabriela Studer; Guido Henke; Lukas Adam; Lukas Anschuetz; Mahmut Ozsahin; Matthias Guckenberger; Mohamed Shelan; Nuri Kaydıhan; Oliver Riesterer; Robin J D Prestwich; Thierry Spielmann; Roland Giger; Mehmet Şen Journal: Front Oncol Date: 2019-09-20 Impact factor: 6.244